Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:ChemMedChem
Autores principales: Karnthaler-Benbakka, Claudia, Groza, Diana, Koblmüller, Bettina, Terenzi, Alessio, Holste, Katharina, Haider, Melanie, Baier, Dina, Berger, Walter, Heffeter, Petra, Kowol, Christian R., Keppler, Bernhard K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151264/
https://ncbi.nlm.nih.gov/pubmed/27706901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600417
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares